// App-Quantinova.ai

BSH2020‐PO‐061 : Managing patients with systemic mastocytosis with associated haematological neoplasm: UK single centre experience

Researchers

Presenter

  • C. Oni

Principal Investigators

  • D. McLornan

  • C. Woodley

  • N. Curto-Garcia

  • Y. Francis

  • A. Green

  • C. Harrison

  • M. Moonim

  • D. Radia

Medical Centers

  • Hematology

  • Histopathology, GSTT, London, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Autoimmune (AI)

  • Pulmonary/Respiratory Diseases

  • Oncology (ONC)

Disease

  • Essential thrombocythemia

  • Mastocytosis

  • Acute Leukemia

  • Myelofibrosis

  • Venous thrombosis

  • Chronic myelomonocytic leukemia

Biomarkers

  • ETV6-RUNX1

  • Hematocrit

  • KIT Proto-Oncogene, Receptor Tyrosine Kinase

  • Tet methylcytosine dioxygenase 2

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Hydroxycarbamide

  • Midostaurin

  • Ruxolitinib phosphate

  • DCC-2618

Outcome

  • N/A

Study Design

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved